BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5

Sara Y. Tartof(Kaiser Permanente), John M. McLaughlin(Pfizer (United States)), Sarah Simmons(Kaiser Permanente), Harpreet S. Takhar(Kaiser Permanente), Timothy B. Frankland(Kaiser Permanente), Vennis Hong(Kaiser Permanente), Oluwaseye Ayoola Ogun(Kaiser Permanente), Jeff Slezak(Kaiser Permanente), Luis Jódar(Pfizer (United States)), Bradley K. Ackerson, Joann M. Zamparo(Pfizer (United States)), Laura Puzniak(Pfizer (United States))

The Lancet Infectious Diseases

October 25, 2022

10.1016/s1473-3099(22)00692-2

Cited by 77

Related Papers

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

|The Lancet|2021|1.7k

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

|The Lancet|2021|1.3k

A Multicenter Study of ICU Telemedicine Reengineering of Adult Critical Care

|CHEST Journal|2014|219

Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis

|Open Forum Infectious Diseases|2022|212

Effect on Survival of Longer Intervals Between Confirmed Diagnosis and Treatment Initiation Among Low-Income Women With Breast Cancer

|Journal of Clinical Oncology|2012|211